688488 艾迪药业
已收盘 07-29 15:00:01
资讯
新帖
简况
艾迪药业：7月27日董事傅和亮增持股份合计13.28万股
证券之星 · 07-28 20:01
艾迪药业：7月27日董事傅和亮增持股份合计13.28万股
7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股
证券之星 · 07-27 16:41
7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股
艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”
证券之星 · 07-25
艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”
7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股
证券之星 · 07-24
7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股
艾迪药业最新公告：达芦那韦片获得药品注册批准
证券之星 · 07-23
艾迪药业最新公告：达芦那韦片获得药品注册批准
7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股
证券之星 · 07-17
7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股
7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股
证券之星 · 07-15
7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股
每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准
证券之星 · 07-12
每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准
艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书
智通财经 · 07-08
艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书
艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作
证券之星 · 07-07
艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作
7月6日艾迪药业涨9.15%，兴全合兴LOF基金重仓该股
证券之星 · 07-06
7月6日艾迪药业涨9.15%，兴全合兴LOF基金重仓该股
艾迪药业：公司2025年年度股东会已审议通过本次向特定对象发行股票预案及配套授权议案
证券之星 · 07-02
艾迪药业：公司2025年年度股东会已审议通过本次向特定对象发行股票预案及配套授权议案
艾迪药业（688488）披露2026年第一次临时股东会决议公告，6月30日股价上涨1.1%
证券之星 · 06-30
艾迪药业（688488）披露2026年第一次临时股东会决议公告，6月30日股价上涨1.1%
6月29日艾迪药业涨9.66%，兴全合兴LOF基金重仓该股
证券之星 · 06-29
6月29日艾迪药业涨9.66%，兴全合兴LOF基金重仓该股
每周股票复盘：艾迪药业（688488）变更保荐机构重签募资监管协议
证券之星 · 06-28
每周股票复盘：艾迪药业（688488）变更保荐机构重签募资监管协议
艾迪药业（688488）披露关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，6月25日股价下跌1.94%
证券之星 · 06-25
艾迪药业（688488）披露关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，6月25日股价下跌1.94%
艾迪药业：公司股权激励计划目前正常执行
证券之星 · 06-23
艾迪药业：公司股权激励计划目前正常执行
每周股票复盘：艾迪药业（688488）拟续聘会计师事务所
证券之星 · 06-20
每周股票复盘：艾迪药业（688488）拟续聘会计师事务所
6月8日艾迪药业跌9.16%，兴全合兴LOF基金重仓该股
证券之星 · 06-08
6月8日艾迪药业跌9.16%，兴全合兴LOF基金重仓该股
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.79万股
证券之星 · 06-07
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.79万股
加载更多
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、药品（尿激酶针剂）、低分子量肝素钠及其他。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":14.73,"timestamp":1785308401000,"preClose":15.48,"halted":0,"volume":9154672,"delay":0,"changeRate":-0.0484,"floatShares":421000000,"shares":421000000,"eps":-0.0654,"marketStatus":"已收盘","change":-0.75,"latestTime":"07-29 15:00:01","open":15.38,"high":15.64,"low":14.4,"amount":138000000,"amplitude":0.0801,"askPrice":14.73,"askSize":258,"bidPrice":14.72,"bidSize":406,"shortable":0,"etf":0,"ttmEps":-0.0654,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785288600000,1785295800000],[1785301200000,1785308400000]],"highLimit":17.03,"lowLimit":13.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":6.36,"roa":"--","roe":"0.78%","epsLYR":-0.05,"committee":0.157696,"marketValue":6198000000,"turnoverRate":0.0218,"status":1,"afterMarket":{"amount":31772.61,"volume":2157,"close":14.73,"buyVolume":2143,"sellVolume":0,"time":1785310437746,"indexStatus":"已收盘 07-29 15:30:00","preClose":15.48},"floatMarketCap":6198000000},"requestUrl":"/m/hq/s/688488/","defaultTab":"news","newsList":[{"id":"2654017770","title":"艾迪药业：7月27日董事傅和亮增持股份合计13.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017770","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654017770?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240104,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月28日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年7月27日公司董事,核心技术人员傅和亮共增持公司股份13.28万股，占公司总股本为0.0316%。变动期间公司股价上涨6.13%，7月27日当日收盘报15.92元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800036019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013648","title":"7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013648?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:41","pubTimestamp":1785141719,"startTime":"0","endTime":"0","summary":"证券之星消息，7月27日艾迪药业涨6.13%，收盘报15.92元，换手率2.68%，成交量11.28万手，成交额1.75亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值2.0104，较上一交易日上涨0.48%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700020970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654342590","title":"艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2654342590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654342590?lang=zh_cn&edition=full","pubTime":"2026-07-25 03:40","pubTimestamp":1784922043,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示艾迪药业新获得一项发明专利授权，专利名为“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”，专利申请号为CN202610561279.3，授权日为2026年7月24日。本发明填补尿源蛋白药物残留蛋白检测空白，特异性强，抗体覆盖率达到70%以上，方法定量限为4ng/ml左右，对于尤瑞克林的残留蛋白检测限低、检测灵敏度高，无需昂贵仪器，操作简便。今年以来艾迪药业新获得专利授权2个，较去年同期增加了100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072500003048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653394700","title":"7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653394700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653394700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:42","pubTimestamp":1784882548,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日艾迪药业跌5.00%，收盘报15.0元，换手率2.38%，成交量10.03万手，成交额1.55亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值2.0008，较上一交易日下跌3.55%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159781","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653404747","title":"艾迪药业最新公告：达芦那韦片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653404747","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653404747?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:00","pubTimestamp":1784808054,"startTime":"0","endTime":"0","summary":"艾迪药业(688488.SH)公告称，近日，公司收到国家药监局核准签发的达芦那韦片《药品注册证书》。达芦那韦片是公司获批的又一款抗HIV领域治疗药物，系国内首仿获批品种，且国内目前暂无其他含达芦那韦活性成分药物上市销售。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300043612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652054214","title":"7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652054214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652054214?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:30","pubTimestamp":1784277044,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日艾迪药业跌9.49%，收盘报15.36元，换手率4.62%，成交量19.43万手，成交额3.01亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为225.78%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","163418"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651536564","title":"7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651536564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651536564?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:23","pubTimestamp":1784103833,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日艾迪药业涨9.22%，收盘报17.17元，换手率8.35%，成交量35.12万手，成交额6.15亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为223.1%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","163418"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650115401","title":"每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650115401?lang=zh_cn&edition=full","pubTime":"2026-07-12 03:12","pubTimestamp":1783797130,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，艾迪药业报收于14.32元，较上周的14.2元上涨0.85%。本周，艾迪药业7月6日盘中最高价报16.19元。本周关注点公司公告汇总：抗艾滋病新药ADC119片获临床试验批准。公司公告汇总艾迪药业关于ADC119片获得药物临床试验批准通知书的自愿性披露公告江苏艾迪药业集团股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药ADC119片开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200001189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299623","title":"艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299623","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649299623?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:01","pubTimestamp":1783515680,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药ADC119片开展临床试验。ADC119 片可通过抑制 HIV 逆转录酶，阻断病毒RNA向DNA的逆转录过程，有效抑制 HIV-1 病毒的复制，临床拟用于治疗HIV-1 感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0262","IBBQ","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649898615","title":"艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649898615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649898615?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:48","pubTimestamp":1783417700,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业(688488)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问非洲等海外市场销售网络搭建及产品进展如何？是否会影响2026年海外收入在总营收中的占比？艾迪药业回复：尊敬的投资者，您好。公司持续推进海外渠道布局与市场拓展相关工作，现阶段海外商业化仍处于前期培育阶段，相关业务经营数据请以公司后续定期报告及官方公告为准。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700030596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649642996","title":"7月6日艾迪药业涨9.15%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649642996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649642996?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:34","pubTimestamp":1783326856,"startTime":"0","endTime":"0","summary":"证券之星消息，7月6日艾迪药业涨9.15%，收盘报15.5元，换手率4.83%，成交量20.32万手，成交额3.12亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为249.71%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163418","BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648771845","title":"艾迪药业：公司2025年年度股东会已审议通过本次向特定对象发行股票预案及配套授权议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2648771845","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648771845?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:37","pubTimestamp":1782977849,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业07月02日在投资者关系平台上答复投资者关心的问题。作为股东，关注到公司2月通过的12.77亿元定增预案因超2个月未召开股东大会或已失效。公司2025年年度股东会已审议通过本次向特定对象发行股票预案及配套授权议案，方案有效期为自公司股东会审议通过本次发行议案之日起12个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200020601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647853441","title":"艾迪药业（688488）披露2026年第一次临时股东会决议公告，6月30日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647853441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647853441?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:53","pubTimestamp":1782813233,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，艾迪药业报收于12.85元，较前一交易日上涨1.1%，最新总市值为54.07亿元。该股当日开盘12.53元，最高13.1元，最低12.46元，成交额达1.27亿元，换手率为2.37%。公司于近日披露《艾迪药业2026年第一次临时股东会决议公告》。公告显示，江苏艾迪药业集团股份有限公司于2026年6月29日召开2026年第一次临时股东会，出席会议的股东及代理人共89人，代表有表决权股份237,470,486股，占公司总表决权股份的56.4354%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647532235","title":"6月29日艾迪药业涨9.66%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647532235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647532235?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:40","pubTimestamp":1782722416,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日艾迪药业涨9.66%，收盘报12.71元，换手率3.64%，成交量15.31万手，成交额1.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为268.68%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163418","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646540315","title":"每周股票复盘：艾迪药业（688488）变更保荐机构重签募资监管协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2646540315","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646540315?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:14","pubTimestamp":1782587653,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，艾迪药业报收于11.59元，较上周的12.57元下跌7.8%。本周，艾迪药业6月24日盘中最高价报12.96元。6月22日盘中最低价报11.4元，股价触及近一年最低点。艾迪药业当前最新总市值48.77亿元，在生物制品板块市值排名38/51，在两市A股市值排名3174/5206。本周关注点公司公告汇总：艾迪药业因变更保荐机构，重新签订募集资金专户存储三方监管协议。协议明确了各方在募集资金管理中的职责，确保专户资金专款专用，并接受持续督导和监管。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809121","title":"艾迪药业（688488）披露关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，6月25日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809121?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:36","pubTimestamp":1782398180,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，艾迪药业报收于12.16元，较前一交易日下跌1.94%，最新总市值为51.17亿元。近日，艾迪药业发布《关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告》。公告显示，公司因变更保荐机构，由国联民生证券承销保荐有限公司担任公司2026年度向特定对象发行A股股票的保荐机构，原与华泰联合证券签订的募集资金三方监管协议终止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645574886","title":"艾迪药业：公司股权激励计划目前正常执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2645574886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645574886?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:37","pubTimestamp":1782200253,"startTime":"0","endTime":"0","summary":"艾迪药业回复：尊敬的投资者，您好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300021339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644406639","title":"每周股票复盘：艾迪药业（688488）拟续聘会计师事务所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644406639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644406639?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:38","pubTimestamp":1781897893,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，艾迪药业报收于12.57元，较上周的12.83元下跌2.03%。本周，艾迪药业6月18日盘中最高价报13.03元。本周关注点来自公司公告汇总：艾迪药业拟续聘公证天业会计师事务所为2026年度审计机构。公司公告汇总江苏艾迪药业集团股份有限公司将召开2026年第一次临时股东会，审议修订《董事、高级管理人员薪酬管理制度》及续聘公证天业会计师事务所为2026年度财务与内部控制审计机构的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107974","title":"6月8日艾迪药业跌9.16%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107974?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:45","pubTimestamp":1780908326,"startTime":"0","endTime":"0","summary":"证券之星消息，6月8日艾迪药业跌9.16%，收盘报12.5元，换手率2.27%，成交量9.56万手，成交额1.24亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为229.18%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","163418"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641924127","title":"每周股票复盘：艾迪药业（688488）董事傅和亮增持7.79万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641924127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641924127?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:34","pubTimestamp":1780770853,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，艾迪药业报收于13.76元，较上周的15.52元下跌11.34%。本周，艾迪药业6月1日盘中最高价报15.69元。6月5日盘中最低价报13.6元。艾迪药业当前最新总市值57.9亿元，在生物制品板块市值排名37/51，在两市A股市值排名3008/5206。变动期间公司股价下跌3.87%，6月2日当日收盘报14.4元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785321136969,"stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":0.3356},{"period":"3month","weight":-0.1052},{"period":"6month","weight":-0.0921},{"period":"1year","weight":-0.014},{"period":"ytd","weight":-0.0521}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"11700人(较上一季度增加7.33%)","perCapita":"35964股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、药品（尿激酶针剂）、低分子量肝素钠及其他。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}